Recent News for IFRX - InflaRx N.V.

Date Title
Mar 25 InflaRx reports FY results
Mar 25 InflaRx Reports Full Year 2020 Financial & Operating Results
Mar 3 InflaRx to Present at Upcoming Investor Conferences
Mar 1 InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
Mar 1 What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)?
Feb 25 InflaRx prices $75M capital raise
Feb 25 InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
Feb 24 InflaRx launches stock offering
Feb 24 InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
Feb 11 InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study
Feb 11 InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
Jan 19 Inflarx (IFRX) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow
Jan 11 InflaRx Provides Update on Vilobelimab (IFX-1) Development
Jan 7 InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
Jan 5 InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 5 InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
Dec 8 These 2 Penny Stocks Could Surge Over 200%, Says Raymond James
Dec 3 Hedge Funds Are Dumping InflaRx N.V. (IFRX)
Nov 12 Will InflaRx (NASDAQ:IFRX) Spend Its Cash Wisely?
Oct 29 InflaRx reports Q3 results
Oct 29 InflaRx Reports Q3 2020 Financial & Operating Results
Back to the Main IFRX Page...